Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOX1 | Q06278 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | LAP3 | P28838 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL921131 | 0.81 | L3MBTL1 (0.46) | L3MBTL1SRCTDP1PKMMEN1 | |
| SCHEMBL3151501 | 0.81 | BTN3A1 (0.51) | AOX1L3MBTL1SRCBTN3A1TDP1 | |
| SCHEMBL5491492 | 0.79 | L3MBTL1 (0.52) | L3MBTL1SRCTDP1PKMMEN1 | |
| SCHEMBL14439890 | 0.78 | L3MBTL1 (0.46) | L3MBTL1SRCTDP1PKMMEN1 | |
| SCHEMBL5490967 | 0.76 | L3MBTL1 (0.49) | L3MBTL1SRCTDP1 | |
| SCHEMBL3624069 | 0.76 | AOX1 (0.50) | AOX1SRCKDM4E | |
| SCHEMBL27749607 | 0.75 | SRC (0.47) | L3MBTL1SRCTDP1ANPEPLAP3 | |
| SCHEMBL14600653 | 0.75 | L3MBTL1 (0.43) | L3MBTL1SRCTDP1PKMMEN1 | |
| SCHEMBL4453718 | 0.75 | BTN3A1 (0.46) | AOX1L3MBTL1SRCBTN3A1TDP1 | |
| SCHEMBL5483772 | 0.75 | L3MBTL1 (0.55) | L3MBTL1SRCTDP1PKMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795464-B2 | Method for producing α-amino acid including phosphorus and production intermediates thereof | MEIJI SEIKA KAISHA LTD. (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20090270647-A1 | METHOD FOR PRODUCING ALPHA - AMINO ACID INCLUDING PHOSPHORUS AND PRODUCTION INTERMEDIATES THEREOF | MEIJI SEIKA KAISHA LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-2065391-A1 | METHOD FOR PRODUCING PHOSPHORUS-CONTAINING -AMINO ACID AND PRODUCTION INTERMEDIATE THEREOF | MEIJI SEIKA KAISHA LTD. (JP) | 2009-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270647-A1 | METHOD FOR PRODUCING ALPHA - AMINO ACID INCLUDING PHOSPHORUS AND PRODUCTION INTERMEDIATES THEREOF | BCAT1, BCAT2, DAO | AOX1 693/4885L3MBTL1 962/4885SRC 4575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.